tooluniverse-gwas-study-explorer
Compare GWAS studies, perform meta-analyses, and assess replication across cohorts. Integrates NHGRI-EBI GWAS Catalog and Open Targets Genetics to compare study designs, effect sizes, ancestry diversity, and heterogeneity statistics. Use when comparing GWAS studies for a trait, performing meta-analysis of genetic loci, assessing replication across cohorts, or exploring the genetic architecture of complex diseases.
Best use case
tooluniverse-gwas-study-explorer is best used when you need a repeatable AI agent workflow instead of a one-off prompt.
Compare GWAS studies, perform meta-analyses, and assess replication across cohorts. Integrates NHGRI-EBI GWAS Catalog and Open Targets Genetics to compare study designs, effect sizes, ancestry diversity, and heterogeneity statistics. Use when comparing GWAS studies for a trait, performing meta-analysis of genetic loci, assessing replication across cohorts, or exploring the genetic architecture of complex diseases.
Teams using tooluniverse-gwas-study-explorer should expect a more consistent output, faster repeated execution, less prompt rewriting.
When to use this skill
- You want a reusable workflow that can be run more than once with consistent structure.
When not to use this skill
- You only need a quick one-off answer and do not need a reusable workflow.
- You cannot install or maintain the underlying files, dependencies, or repository context.
Installation
Claude Code / Cursor / Codex
Manual Installation
- Download SKILL.md from GitHub
- Place it in
.claude/skills/tooluniverse-gwas-study-explorer/SKILL.mdinside your project - Restart your AI agent — it will auto-discover the skill
How tooluniverse-gwas-study-explorer Compares
| Feature / Agent | tooluniverse-gwas-study-explorer | Standard Approach |
|---|---|---|
| Platform Support | Not specified | Limited / Varies |
| Context Awareness | High | Baseline |
| Installation Complexity | Unknown | N/A |
Frequently Asked Questions
What does this skill do?
Compare GWAS studies, perform meta-analyses, and assess replication across cohorts. Integrates NHGRI-EBI GWAS Catalog and Open Targets Genetics to compare study designs, effect sizes, ancestry diversity, and heterogeneity statistics. Use when comparing GWAS studies for a trait, performing meta-analysis of genetic loci, assessing replication across cohorts, or exploring the genetic architecture of complex diseases.
Where can I find the source code?
You can find the source code on GitHub using the link provided at the top of the page.
SKILL.md Source
# GWAS Study Deep Dive & Meta-Analysis
**Compare GWAS studies, perform meta-analyses, and assess replication across cohorts**
---
## Overview
The GWAS Study Deep Dive & Meta-Analysis skill enables comprehensive comparison of genome-wide association studies (GWAS) for the same trait, meta-analysis of genetic loci across studies, and systematic assessment of replication and study quality. It integrates data from the NHGRI-EBI GWAS Catalog and Open Targets Genetics to provide a complete picture of the genetic architecture of complex traits.
### Key Capabilities
1. **Study Comparison**: Compare all GWAS studies for a trait, assessing sample sizes, ancestries, and platforms
2. **Meta-Analysis**: Aggregate effect sizes across studies and calculate heterogeneity statistics
3. **Replication Assessment**: Identify replicated vs novel findings across discovery and replication cohorts
4. **Quality Evaluation**: Assess statistical power, ancestry diversity, and data availability
---
## Use Cases
### 1. Comprehensive Trait Analysis
**Scenario**: "I want to understand all available GWAS data for type 2 diabetes"
**Workflow**:
- Search for all T2D studies in GWAS Catalog
- Filter by sample size and ancestry
- Extract top associations from each study
- Identify consistently replicated loci
- Assess ancestry-specific effects
**Outcome**: Complete landscape of T2D genetics with replicated findings and population-specific signals
### 2. Locus-Specific Meta-Analysis
**Scenario**: "Is the TCF7L2 association with T2D consistent across all studies?"
**Workflow**:
- Retrieve all TCF7L2 (rs7903146) associations for T2D
- Calculate combined effect size and p-value
- Assess heterogeneity (I² statistic)
- Generate forest plot data
- Interpret heterogeneity level
**Outcome**: Quantitative assessment of effect size consistency with heterogeneity interpretation
### 3. Replication Analysis
**Scenario**: "Which findings from the discovery cohort replicated in the independent sample?"
**Workflow**:
- Get top hits from discovery study
- Check for presence and significance in replication study
- Assess direction consistency
- Calculate replication rate
- Identify novel vs failed replication
**Outcome**: Systematic replication report with success rates and failed findings
### 4. Multi-Ancestry Comparison
**Scenario**: "Are T2D loci consistent across European and East Asian populations?"
**Workflow**:
- Filter studies by ancestry
- Compare top associations between populations
- Identify shared vs population-specific loci
- Assess allele frequency differences
- Evaluate transferability of genetic risk scores
**Outcome**: Ancestry-specific genetic architecture with transferability assessment
---
## Statistical Methods
### Meta-Analysis Approach
This skill implements standard GWAS meta-analysis methods:
**Fixed-Effects Model**:
- Used when heterogeneity is low (I² < 25%)
- Weights studies by inverse variance
- Assumes true effect size is the same across studies
**Random-Effects Model** (recommended when I² > 50%):
- Accounts for between-study variation
- More conservative than fixed-effects
- Better for diverse ancestries or methodologies
**Heterogeneity Assessment**:
The **I² statistic** measures the percentage of variance due to between-study heterogeneity:
```
I² = [(Q - df) / Q] × 100%
where Q = Cochran's Q statistic
df = degrees of freedom (n_studies - 1)
```
**Interpretation Guidelines**:
- **I² < 25%**: Low heterogeneity → fixed-effects appropriate
- **I² = 25-50%**: Moderate heterogeneity → investigate sources
- **I² = 50-75%**: Substantial heterogeneity → random-effects preferred
- **I² > 75%**: Considerable heterogeneity → meta-analysis may not be appropriate
### Sources of Heterogeneity
Common reasons for high I²:
1. **Ancestry differences**: Different allele frequencies and LD structure
2. **Phenotype heterogeneity**: Trait definition varies across studies
3. **Platform differences**: Imputation quality and coverage
4. **Winner's curse**: Discovery studies overestimate effect sizes
5. **Cohort characteristics**: Age, sex, environmental factors
**Recommendations**:
- Perform subgroup analysis by ancestry
- Use meta-regression to investigate sources
- Consider excluding outlier studies
- Apply genomic control correction
---
## Study Quality Assessment
### Quality Metrics
The skill evaluates studies based on:
**1. Sample Size**:
- Power to detect associations (80% power requires n > 10,000 for OR=1.2)
- Precision of effect size estimates
- Ability to detect modest effects
**2. Ancestry Diversity**:
- Single-ancestry vs multi-ancestry
- Population stratification control
- Transferability of findings
**3. Data Availability**:
- Summary statistics available for meta-analysis
- Individual-level data vs summary-level
- Imputation quality scores
**4. Genotyping Quality**:
- Platform density and coverage
- Imputation reference panel
- Quality control measures
**5. Statistical Rigor**:
- Genome-wide significance threshold (p < 5×10⁻⁸)
- Multiple testing correction
- Replication in independent cohort
### Quality Tiers
**Tier 1 (High Quality)**:
- n ≥ 50,000
- Summary statistics available
- Multi-ancestry or large single-ancestry
- Imputed to high-quality reference
- Independent replication
**Tier 2 (Moderate Quality)**:
- n ≥ 10,000
- Standard GWAS platform
- Adequate power for common variants
- Some data availability
**Tier 3 (Limited)**:
- n < 10,000
- Limited power
- May miss modest effects
- Use with caution
---
## Best Practices
### Before Meta-Analysis
1. **Check phenotype consistency**: Ensure studies measure the same trait
2. **Verify ancestry overlap**: High heterogeneity expected if ancestries differ
3. **Harmonize alleles**: Align effect alleles across studies
4. **Quality control**: Exclude low-quality studies or associations
### Interpreting Results
1. **Genome-wide significance**: p < 5×10⁻⁸ (Bonferroni for ~1M independent tests)
2. **Replication threshold**: p < 0.05 in independent cohort
3. **Direction consistency**: Effect should be same direction across studies
4. **Heterogeneity**: I² > 50% suggests caution in interpretation
### Common Pitfalls
❌ **Don't**:
- Meta-analyze without checking heterogeneity
- Ignore ancestry differences
- Over-interpret nominal p-values
- Assume replication failure means false positive
✅ **Do**:
- Always report I² statistic
- Perform sensitivity analyses
- Consider ancestry-stratified analysis
- Account for winner's curse in discovery studies
---
## Limitations & Caveats
### Data Limitations
1. **Incomplete Overlap**: Studies may analyze different SNPs
2. **Cohort Overlap**: Some cohorts participate in multiple studies (inflates significance)
3. **Publication Bias**: Significant findings more likely to be published
4. **Winner's Curse**: Discovery studies overestimate effect sizes
5. **Imputation Quality**: Varies across studies and populations
### Statistical Limitations
1. **Heterogeneity**: High I² may preclude meaningful meta-analysis
2. **Sample Size Differences**: Large studies dominate fixed-effects models
3. **Allele Frequency Differences**: Same variant has different effects across ancestries
4. **Linkage Disequilibrium**: Fine-mapping needed to identify causal variants
5. **Gene-Environment Interactions**: Not captured in standard meta-analysis
### Interpretation Guidelines
**When I² > 75%**:
- Meta-analysis results should be interpreted with extreme caution
- Investigate sources of heterogeneity systematically
- Consider ancestry-specific or subgroup analyses
- Descriptive comparison may be more appropriate than meta-analysis
**When Studies Conflict**:
- Check for methodological differences
- Verify phenotype definitions match
- Investigate population stratification
- Consider conditional analysis
---
## Scientific References
### Key Publications
1. **GWAS Best Practices**:
- Visscher et al. (2017). "10 Years of GWAS Discovery" *American Journal of Human Genetics* 101(1): 5-22
- PMID: 28686856
- DOI: 10.1016/j.ajhg.2017.06.005
2. **Meta-Analysis Methods**:
- Evangelou & Ioannidis (2013). "Meta-analysis methods for genome-wide association studies and beyond" *Nature Reviews Genetics* 14: 379-389
- PMID: 23657481
3. **Heterogeneity Interpretation**:
- Higgins et al. (2003). "Measuring inconsistency in meta-analyses" *BMJ* 327: 557-560
- PMID: 12958120
4. **Multi-Ancestry GWAS**:
- Peterson et al. (2019). "Genome-wide Association Studies in Ancestrally Diverse Populations" *Nature Reviews Genetics* 20: 409-422
- PMID: 30926972
5. **Replication Standards**:
- Chanock et al. (2007). "Replicating genotype-phenotype associations" *Nature* 447: 655-660
- PMID: 17554299
---
## Tools Used
### GWAS Catalog API
- `gwas_search_studies`: Find studies by trait
- `gwas_get_study_by_id`: Get detailed study metadata
- `gwas_get_associations_for_study`: Retrieve study associations
- `gwas_get_associations_for_snp`: Get SNP associations across studies
- `gwas_search_associations`: Search associations by trait
### Open Targets Genetics GraphQL API
- `OpenTargets_search_gwas_studies_by_disease`: Disease-based study search
- `OpenTargets_get_gwas_study`: Detailed study information with LD populations
- `OpenTargets_get_variant_credible_sets`: Fine-mapped loci for variant
- `OpenTargets_get_study_credible_sets`: All credible sets for study
- `OpenTargets_get_variant_info`: Variant annotation and allele frequencies
---
## Glossary
**Association**: Statistical relationship between a genetic variant and a trait
**Credible Set**: Set of variants likely to contain the causal variant (from fine-mapping)
**Effect Size**: Magnitude of genetic association (beta coefficient or odds ratio)
**Fine-Mapping**: Statistical method to identify causal variants within a locus
**Genome-Wide Significance**: p < 5×10⁻⁸, accounting for ~1M independent tests
**Heterogeneity (I²)**: Percentage of variance due to between-study differences
**L2G (Locus-to-Gene)**: Score predicting which gene is affected by a GWAS locus
**LD (Linkage Disequilibrium)**: Non-random association of alleles at different loci
**Meta-Analysis**: Statistical combination of results from multiple studies
**Replication**: Independent confirmation of an association in a new cohort
**Summary Statistics**: Per-SNP statistics (p-value, beta, SE) from GWAS
**Winner's Curse**: Overestimation of effect size in discovery studies
---
## Next Steps
After running this skill, consider:
1. **Fine-Mapping**: Use credible sets from Open Targets to identify causal variants
2. **Functional Follow-Up**: Investigate biological mechanisms of replicated loci
3. **Genetic Risk Scores**: Calculate polygenic risk scores using validated loci
4. **Drug Target Identification**: Use L2G scores to prioritize therapeutic targets
5. **Cross-Trait Analysis**: Look for pleiotropy with related traits
---
## Version History
- **v1.0** (2026-02-13): Initial release with study comparison, meta-analysis, and replication assessment
---
**Created by**: ToolUniverse GWAS Analysis Team
**Last Updated**: 2026-02-13
**License**: Open source (MIT)Related Skills
tooluniverse-target-research
Gather comprehensive biological target intelligence from 9 parallel research paths covering protein info, structure, interactions, pathways, expression, variants, drug interactions, and literature. Features collision-aware searches, evidence grading (T1-T4), explicit Open Targets coverage, and mandatory completeness auditing. Use when users ask about drug targets, proteins, genes, or need target validation, druggability assessment, or comprehensive target profiling.
tooluniverse-protein-therapeutic-design
Design novel protein therapeutics (binders, enzymes, scaffolds) using AI-guided de novo design. Uses RFdiffusion for backbone generation, ProteinMPNN for sequence design, ESMFold/AlphaFold2 for validation. Use when asked to design protein binders, therapeutic proteins, or engineer protein function.
tooluniverse-pharmacovigilance
Analyze drug safety signals from FDA adverse event reports, label warnings, and pharmacogenomic data. Calculates disproportionality measures (PRR, ROR), identifies serious adverse events, assesses pharmacogenomic risk variants. Use when asked about drug safety, adverse events, post-market surveillance, or risk-benefit assessment.
tooluniverse-network-pharmacology
Construct and analyze compound-target-disease networks for drug repurposing, polypharmacology discovery, and systems pharmacology. Builds multi-layer networks from ChEMBL, OpenTargets, STRING, DrugBank, Reactome, FAERS, and 60+ other ToolUniverse tools. Calculates Network Pharmacology Scores (0-100), identifies repurposing candidates, predicts mechanisms, and analyzes polypharmacology. Use when users ask about drug repurposing via network analysis, multi-target drug effects, compound-target-disease networks, systems pharmacology, or polypharmacology.
tooluniverse-drug-target-validation
Comprehensive computational validation of drug targets for early-stage drug discovery. Evaluates targets across 10 dimensions (disambiguation, disease association, druggability, chemical matter, clinical precedent, safety, pathway context, validation evidence, structural insights, validation roadmap) using 60+ ToolUniverse tools. Produces a quantitative Target Validation Score (0-100) with GO/NO-GO recommendation. Use when users ask about target validation, druggability assessment, target prioritization, or "is X a good drug target for Y?"
tooluniverse-drug-research
Generates comprehensive drug research reports with compound disambiguation, evidence grading, and mandatory completeness sections. Covers identity, chemistry, pharmacology, targets, clinical trials, safety, pharmacogenomics, and ADMET properties. Use when users ask about drugs, medications, therapeutics, or need drug profiling, safety assessment, or clinical development research.
tooluniverse-drug-repurposing
Identify drug repurposing candidates using ToolUniverse for target-based, compound-based, and disease-driven strategies. Searches existing drugs for new therapeutic indications by analyzing targets, bioactivity, safety profiles, and literature evidence. Use when exploring drug repurposing opportunities, finding new indications for approved drugs, or when users mention drug repositioning, off-label uses, or therapeutic alternatives.
tooluniverse-drug-drug-interaction
Comprehensive drug-drug interaction (DDI) prediction and risk assessment. Analyzes interaction mechanisms (CYP450, transporters, pharmacodynamic), severity classification, clinical evidence grading, and provides management strategies. Supports single drug pairs, polypharmacy analysis (3+ drugs), and alternative drug recommendations. Use when users ask about drug interactions, medication safety, polypharmacy risks, or need DDI assessment for clinical decision support.
tooluniverse-chemical-safety
Comprehensive chemical safety and toxicology assessment integrating ADMET-AI predictions, CTD toxicogenomics, FDA label safety data, DrugBank safety profiles, and STITCH chemical-protein interactions. Performs predictive toxicology (AMES, DILI, LD50, carcinogenicity), organ/system toxicity profiling, chemical-gene-disease relationship mapping, regulatory safety extraction, and environmental hazard assessment. Use when asked about chemical toxicity, drug safety profiling, ADMET properties, environmental health risks, chemical hazard assessment, or toxicogenomic analysis.
tooluniverse-chemical-compound-retrieval
Retrieves chemical compound information from PubChem and ChEMBL with disambiguation, cross-referencing, and quality assessment. Creates comprehensive compound profiles with identifiers, properties, bioactivity, and drug information. Use when users need chemical data, drug information, or mention PubChem CID, ChEMBL ID, SMILES, InChI, or compound names.
tooluniverse-binder-discovery
Discover novel small molecule binders for protein targets using structure-based and ligand-based approaches. Creates actionable reports with candidate compounds, ADMET profiles, and synthesis feasibility. Use when users ask to find small molecules for a target, identify novel binders, perform virtual screening, or need hit-to-lead compound identification.
tooluniverse-antibody-engineering
Comprehensive antibody engineering and optimization for therapeutic development. Covers humanization, affinity maturation, developability assessment, and immunogenicity prediction. Use when asked to optimize antibodies, humanize sequences, or engineer therapeutic antibodies from lead to clinical candidate.